Hong Kong reforms advance amid industry concerns
This article was originally published in Scrip
Executive Summary
Despite signs that funding for innovative and effective drugs could be increased, the research-based pharmaceutical industry remains cautious towards the planned reform of Hong Kong's public healthcare system, saying that much clearer proposals are needed on the financing and other aspects.